Has Jean Bien-Aime received payments from drug or device companies?

Yes. Drug and device makers reported $7,191 in general payments to Jean Bien-Aime across 289 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jean Bien-Aime did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jean Bien-Aime come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jean Bien-Aime

Psychiatry · Brooklyn, NYNPI 1003991480

Payments from drug & device makers

$7,191in general payments, 2019–2025

Across 289 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$3K
Neurocrine Biosciences, Inc.$2K
Sunovion Pharmaceuticals Inc.$579
Lundbeck LLC$535
Alkermes, Inc.$413
E.r. Squibb & Sons, L.L.C.$288
plus $681 from 4 others

What the payments were for

Food & beverage$7,180100%
Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	106	$2,595
Neurocrine Biosciences, Inc.	70	$2,100
Sunovion Pharmaceuticals Inc.	28	$579
Lundbeck LLC	26	$535
Alkermes, Inc.	15	$413
E.r. Squibb & Sons, L.L.C.	12	$288
Teva Pharmaceuticals USA, Inc.	11	$270
Johnson & Johnson	10	$219
Corium, LLC	6	$127
Viiv Healthcare Company	5	$65

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,191 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega SustennaPaliperidone Palmitate	60	$111,312
RexultiBrexpiprazole	62	$85,716
AustedoDeutetrabenazine	12	$81,136
Abilify MaintenaAripiprazole	27	$69,897
Lurasidone Hcl	88	$23,750
TrintellixVortioxetine Hydrobromide	13	$5,957
Aripiprazole	101	$3,735
Fluphenazine Hcl	64	$2,532
Bupropion XlBupropion Hcl	123	$1,781
Divalproex Sodium ErDivalproex Sodium	84	$1,628
Haloperidol	114	$1,587
Quetiapine Fumarate	234	$1,359
Clozapine	29	$1,322
Ziprasidone Hcl	23	$1,142
Benztropine Mesylate	131	$937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena	$2,595	$155,61389 claims
Johnson & JohnsonInvega Sustenna	$219	$111,31260 claims
Teva Pharmaceuticals USA, Inc.Austedo	$270	$81,13612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

Inna Yuryev-GolgerBrooklyn$3M
Zinoviy BenzarBrooklyn$505K
Nikhil PalekarBrooklyn$481K
Mark OwensBrooklyn$286K
Elyssa BarronWhite Plains$12.8M
Mark DibuonoStaten Island$11.9M
Ronald BrennerHempstead$11.5M
Anton PorsteinssonRochester$7.6M
Michael LiebowitzNew York$7.1M
Leslie CitromePomona$5.7M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →